-
Company Profile
![]()
Biohaven Pharmaceutical Holding Company Ltd – Company Profile
Biohaven Pharmaceutical Holding Company Ltd (Biohaven) is a clinical-stage biopharmaceutical company. The company develops late-stage product candidates for neurological diseases. The company develops small molecule CGRP receptor antagonist platform that includes two product candidates such as rimegepant for the acute treatment of migraine, and zavegepant for the prevention of a chronic and episodic migraine. Its glutamate modulation platform includes product candidates such as trigriluzole and BHV-4157 for the treatment of obsessive-compulsive disorder (OCD) and Alzheimer’s disease, BHV-0223 for the treatment...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – APG-157 in Oropharyngeal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. APG-157 in Oropharyngeal Cancer Drug Details: APG-157Â is under development for the treatment of recurrent high-grade...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HL-237 in Rheumatoid Arthritis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDataÂ’s proprietary machine learning algorithms developed using over 10 years of historical data. HL-237 in Rheumatoid Arthritis Drug Details: HL-237 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TLL-041 in Alzheimer’s Disease
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TLL-041 in Alzheimer's Disease Drug Details: BHV-8000 (TLL-041) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TLL-041 in Multiple Sclerosis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TLL-041 in Multiple Sclerosis Drug Details: BHV-8000 (TLL-041) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TLL-041 in Parkinson’s Disease
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TLL-041 in Parkinson's Disease Drug Details: BHV-8000 (TLL-041) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TLL-041 in Amyotrophic Lateral Sclerosis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TLL-041 in Amyotrophic Lateral Sclerosis Drug Details: BHV-8000 (TLL-041) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TLL-041 in Autoimmune Encephalitis (Post-Infectious)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TLL-041 in Autoimmune Encephalitis (Post-Infectious) Drug Details: BHV-8000 (TLL-041) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BHV-1100 in Multiple Myeloma (Kahler Disease)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BHV-1100 in Multiple Myeloma (Kahler Disease) Drug Details:BHV-1100 is under development for the treatment of multiple...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ocedurenone in Chronic Kidney Disease (Chronic Renal Failure)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocedurenone in Chronic Kidney Disease (Chronic Renal Failure) Drug Details: Ocedurenone (KBP-5074) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Verdiperstat in Aphasia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Verdiperstat in AphasiaDrug Details:Verdiperstat (AZD-3241) is under development for the treatment of multiple system atrophy, amyotrophic lateral...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Talditercept Alfa in Spinal Muscular Atrophy (SMA)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Talditercept Alfa in Spinal Muscular Atrophy (SMA) Drug Details: Talditercept alfa (RG-6206) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TQB-3454 in Astrocytoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TQB-3454 in Astrocytoma Drug Details: TQB-3454 is under development for the treatment of metastatic solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BBP-398 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BBP-398 in Non-Small Cell Lung Cancer Drug Details:BBP-398 is under development for the treatment of treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Verdiperstat in Amyotrophic Lateral Sclerosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Verdiperstat in Amyotrophic Lateral Sclerosis Drug Details:Verdiperstat (AZD-3241) is under development for the treatment of multiple...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nacubactam in Gram-Negative Bacterial Infections
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nacubactam in Gram-Negative Bacterial Infections Drug Details: Nacubactam (RG6080, RO7079901) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Verdiperstat in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Verdiperstat in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)Drug Details:Verdiperstat (AZD-3241) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Troriluzole Hydrochloride in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Troriluzole Hydrochloride in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Troriluzole Hydrocholride (trigriluzole, BHV-4157) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Balstilimab in Squamous Cell Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Balstilimab in Squamous Cell Carcinoma Drug Details:AGEN-2034 (balstilimab) is under development for the treatment of metastatic angiosarcoma,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NEO-2734 in Castration-Resistant Prostate Cancer (CRPC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.NEO-2734 in Castration-Resistant Prostate Cancer (CRPC) Drug Details:NEO-2734 is under development for the treatment of solid...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.